COLO B Coloplast A/S Class B

Announcement no. 06/2019 - The French Ministry of Health has announced a price reform within Ostomy Care, Continence Care and Wound Care

Announcement no. 06/2019 - The French Ministry of Health has announced a price reform within Ostomy Care, Continence Care and Wound Care

Following a reimbursement review the French Ministry of Health has published new final classifications and prices within Ostomy Care, Continence Care and Wound Care in France. The new classifications and prices will be implemented as of 1 July 2019 for Ostomy Care and Continence Care and have been implemented as of 1 June 2019 for Wound Care.

For Coloplast, the price reform represents an average reduction in prices in France for Ostomy Care and Continence Care of ~9% and Wound Care of ~2%.

For 2017/18, Coloplast reported revenues of around DKK 1.7bn in Ostomy Care and Continence Care in France.

Coloplast continues to analyse the final impact of the reform and will implement mitigating activities.  

Coloplast’s full year financial guidance for 2018/19 is unchanged as a result of the price reform.

Coloplast will provide guidance for 2019/20 in connection with our FY 2018/19 results on 5 November 2019.

Coloplast’s long-term guidance financial guidance for the LEAD20 strategy period running until end 2019/20 is an annual organic growth of 7-9%, and an EBIT margin of more than 30% at constant exchange rates. 

Coloplast A/S



For more information, please contact:

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Ellen Bjurgert

Vice President, Investor Relations

Tel. / 4911 3376

E-mail

Rasmus Sørensen

Senior Manager, Investor Relations

Tel. / 4911 1786

E-mail

Press and the media

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

Tel.

E-mail

Attachment

EN
01/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Coloplast AS: 1 director

A director at Coloplast AS maiden bought 2,000 shares at 447.000DKK and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

 PRESS RELEASE

Coloplast A/S - Allokering af aktieoptioner

Coloplast A/S - Allokering af aktieoptioner Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med Coloplast aktier og tilknyttede værdipapirer I henhold til Markedsmisbrugsforordningen art. 19 skal Coloplast indberette oplysninger om ledende medarbejderes og disses nærtståendes transaktioner med Coloplast aktier og tilknyttede værdipapirer. Transaktionen omhandler allokeringer af aktieoptioner. For yderligere information henvises til Coloplasts vederlagspolitik som er tilgængelig på Coloplasts hjemmeside: 1Nærmere oplysninger om personen med ledelsesansvar/per...

 PRESS RELEASE

Coloplast A/S - Allocation of Share Options

Coloplast A/S - Allocation of Share Options Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address:  Details of the person discharging managerial responsibilities/p...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch